Hair Loss Cure 2020 | Hair loss blog with the latest news updates.

During the past two years, a large number of unique and promising topical hair growth cosmeceuticals have entered the market. None of these have gone through clinical trials, since cosmetic type products can be released in this manner. All of these cosmeceuticals (listed below) do have some legitimate science behind their potential efficacy.

This rapid proliferation of new well researched cosmeceuticals that can be purchased online to fight hair loss is encouraging. Even if many of the beneficial claims (sometimes in mice) turn out to be exaggerated. Hair loss sufferers are tired of lengthy clinical trials that ultimately lead to nowhere. So I for one am glad about this “shortcut” to market. Most importantly, we have thus far not heard of any major issues with side effects from any of these newly available hair loss products.

Note that the term “cosmeceutical” is a portmanteau of the words “cosmetic” and “pharmaceutical”. However, the FDA does not recognize it, and says that such a product has to be classified as: a (topical) drug, or a cosmetic, or both.

New Topical Hair Growth Cosmeceuticals

CosmeRNA for hair loss.
The product that started this recent trend was CosmeRNA, first released in May 2023 in Western Europe by Bioneer (South Korea). In 2024, it was released in the US on Amazon. CosmeRNA targets the androgen receptor via self-assembled micelle inhibitory RNA (SAMiRNA) nanoparticle-type siRNA. Prior to the product’s release, the scientists behind its development published a study in Nature in January 2022.
Yuva Biosciences BosleyMD Revive+ Foam for Hair Loss.
In February 2024, Bosley (US) and Yuva Biosciences (US) together released a new hair loss foam product that works by boosting mitochondria levels in scalp hair. It contains Yuva’s Y100™ small molecule that improves mitochondrial function, and is sold on Amazon.
Moreover, in December 2024, Elevai Labs (US) and Yuva launched a new line of hair loss products (shampoo, conditioner and serum) that contain Elevai ‘s PREx Exosomes™ and Yuva’s Y100™. Also of note, Atticus Pharma (US) is working on a hair growth topical product that will deliver a mitochondrial-activating molecule using the company’s Z-pod sustained-release technology.
Kintor Hair Loss Cosmeceutical.
In June 2024, Kintor Pharmaceutical (China) released its much anticipated KX-826 (pyrilutamide) hair growth spray on Amazon. While the original version was at a strength of 0.5%, the company released a higher-strength version in 2025. This was followed by two additional versions, including a foam.
KX-826 is an androgen receptor antagonist, and is currently in Phase 3 clinical trials in both China and the US. It is expected to get released in China in 2027. Meanwhile, for the time being, we have the option to buy the cosmecutical version of KX-826 from Amazon.
In October 2025, a South Korea based company called AriBio received permission from the Ministry of Food and Drug Safety to market its TeloAct product as a hair loss cosmetic. This topical product activates telomerase enzymes, which supposedly helps prevent hair loss due to telomere shortening. Read more about this in my post on telomerase activation and hair growth.
In November 2025, Mallia Therapeutics (Germany) released its 8T3 Essentials Hair Serum. This hair growth product is based on a molecule called MAL-838, which is derived from a soluble version of the CD83 protein (aka sCD83). Research has indicated that hair follicle formation and wound healing are improved in CD83-treated mice.
Coegin Pharma (Sweden) will release its Follicopeptide hair growth product in December 2025. This osteopontin-derived peptide product for hair growth has a decade of research behind it via Follicum (a company that was purchased by Coegin in 2022).
A number of topical exosome products for hair growth were released in 2024 and 2025, with Calecim getting the most publicity. Some of them are only available at doctor or surgeon offices and often applied after scalp microneedling.

Other Potential Future Topical Hair Loss Cosmeceuticals

In July 2024, a study from the UK captured global media attention due to its viral finding that a naturally occurring sugar (2-deoxy-D-ribose — 2dDr) could reverse hair loss. The results were only in mice, and I doubt that anything significant will be seen in humans. Nevertheless, the scientists behind these findings plan to further research the potential of developing a topically delivered sugar gel product for human scalps. Meanwhile, a number of companies and entrepreneurs have already started selling cosmeceuticals based on 2dDr online.

OliX Pharmaceuticals (South Korea) is conducting Phase 2 clinical trials for its topical hair growth product OLX104C that targets the androgen receptor. In the meantime, in June 2025, they launched a functional hair loss cosmetic called U:BERNA. However, it is unclear if there is any link to OLX104C in terms of mechanism of action.

In October 2025, we heard about a new fatty acid serum from Taiwan that will likely be a cosmeceutical if and when released. The product will not need to go through any clinical trials since its fatty acid ingredients are already well established and safe.

Energenesis (Taiwan) is working on a topical AMP-activated protein kinase (AMPK) hair growth cosmetic product. It boosts the adenosine triphosphate (ATP) levels of human follicle dermal papilla cells. On a related note, Spain-based Ideeea Therapeutics is working on developing an injectable treatment consisting allogeneic mesenchymal stem cells (derived from adipose tissue) combined with ATP.

Topical androgen receptor inhibitor Breezula from Cosmo Pharmaceuticals (Ireland) is also currently in Phase 3 clinical trials. Unlike what Kintor did with its earlier mentioned androgen receptor antagonist, Cosmo does not plan to release any cosmeceutical version of Breezula in advance of official government approval for its main product.

Note that the much anticipated PP405 from Pelage Pharmceuticals is a topical hair loss product that will enter Phase 3 clinical trials in 2026. However, it does not seem like the company plans to release any cosmeceutical version in advance.

Hope Medicine’s HMI-115 prolactin blocker is delivered via injection, so it is not exactly a topical (lotion, cream, gel or spray). But I will still mention it here since it has completed Phase 2 trials and is also very eagerly awaited.

In 2014, I wrote two posts about the US-made ARTAS hair transplant robot after its manufacturer announced the sale of its 100th unit. ARTAS is used for follicular unit extraction (FUE) during hair restoration procedures. It was first approved by the US FDA in 2011, and has since monopolized the global robotic hair transplant market.

However, it now seems like ARTAS will finally face competition from China’s new and much cheaper HAIRO hair transplant robot. In less than a year, 30 HAIRO units have been sold in China, at a per unit price of just one-quarter of ARTAS.

HAIRO Hair Transplant Robot from China

The HAIRO AI-powered hair transplant robot is made by China’s Puncture Robotic and it came out in January 2025. Per a recent article covering this device, Puncture Robotic has already sold around 30 units of HAIRO in China. Sales expanded after the device received the medical device usage green light from China’s National Medical Products Administration.

Using 3D imaging and AI, the HAIRO hair transplant robot can extract up to 1,800 hair follicle units per hour. Ultimately, this precision driven robot will cause less extraction related skin trauma compared to regular human graft extraction. Especially if the human extractors are not very experienced, well trained or just having a bad “human” day. Quote:

“Compared to traditional manual hair transplants, the first-generation hair transplant robot achieves a 95 percent accuracy rate in automatic follicle extraction, with each follicle taking less than 2 seconds to extract, and extraction precision reaching 0.01 millimeters, and depth precision at 0.05 millimeters.”

HAIRO’s AI also prioritizes the extraction of multi-stranded follicles (i.e., grafts containing more than one hair). When transplanted, such grafts create a denser look. HAIRO can achieve a maximum multi-follicle extraction rate of 95 percent, versus an average 65% manual multi-follicle extraction rate.

Also of interest, scientists from Thailand published an insanely detailed paper in February 2025 where they outlined how to develop an integrated image-guided robotic system for hair transplant surgery. Well worth a full read for those who are interested in this kind of technology.

HAIRO Cost

According to Puncture Robotic co-founder He Yundi, ARTAS was priced at between 6 million to 8 million yuan in China (equal to around $840,000 to $1.1 million). In contrast, the HAIRO hair transplant robot costs only about a quarter of this total (i.e., $210,000 to $280,000). Mr. He claims that this is the key factor that led ARTAS to exit the Chinese market.

China’s Hair Transplant Market

I constantly read new articles that mention an ever increasing number of people are losing their hair in China and India, the two world’s most populated countries. In the past, I even used to collect these links and add them in my post titled: “Are men losing their hair at earlier ages than in past generations?“.

In the latest article about HAIRO that I linked to earlier, it is mentioned that the number of new hair transplant clinics that opened in China rose from 15 in 2012 to 119 in 2021. This number then dropped to 89 in 2022, but the overall growth is still spectacular. However, China is still no match for Turkey, where the number of existing hair transplant clinics is though to exceed 5,000. Albeit many of these are substandard and often un-authorized black market entities.

A report by MRFR on China’s hair transplant sector put the market’s value at $367.5 million in 2024, and projected that it would hit $1.2 billion in a decade. The mraket for robotic hair transplants in China will rise from $90 million in 2024 to $216 million in 2035.